[Image: 1910 Genetics]
The pharmaceutical industry is at a critical juncture: AI and other technological advances offer unprecedented potential, yet the cost of developing new drugs has ballooned for decades, surpassing $2 billion in recent years with the projected return on investment (ROI) falling to a mere 1.2% in 2022, according to Deloitte. Another dimension of the problem is the high failure rate — many potential drugs fall short in the expensive clinical trials.Microsoft and 1910 Genetics have announced a partnership that aims to reverse the troubling trend.
Accelerating discovery with AI and quantum-inspired computingMicrosoft’s Azure Quantum Elements is at the core of this alliance. The platform integrates high-performance computing, AI, and quantum techniques for faster scientific discovery in chemistry and materials science. The goal is to democratize technologies like AI, high-performa…